ライフサイエンスコーパス: were @1 years of age or older

1 ries were included if they had no diagnosis of AMD in 1997, were 65 years of age or older, had data through 2009, and had

2 he overall median age of the patients was 33 years, and 40% were 40 years of age or older; 73% of the patients had interm

3 tic participants recruited at 15 centers for the trial, 497 were 65 years of age or older.

4 he patients were children under the age of 18 years, and 5% were 65 years of age or older.

5 The majority of patients (127 of 147, 86%) were 60 years of age or older.

6 ical ventilation met the criteria for acute lung injury and were 15 years of age or older.

7 were selected from 42 Veterans Affairs medical centers and were 49 years of age or older at the time of registration.

8 All participants were 12 years of age or older and had severe hemophilia B (en

9 Eligible participants were 40 years of age or older, did not have EG or EGS at base

10 Eligible patients were 18 years of age or older, had limited-stage or extensive

11 In 1997, 68 percent of the patients were 18 years of age or older.

12 Eligible patients were 40 years of age or older with a smoking history of at le

13 Ninety of the patients were 80 years of age or older; of these, 38 underwent COR and

14 which patients with atypical hemolytic-uremic syndrome who were 12 years of age or older received eculizumab for 26 week

15 vention (307.8 mmol sodium/day) among 1,906 individuals who were 16 years of age or older and living in rural northern Ch

16 In this clustered randomised trial, PWID who were 16 years of age or older, had used self-reported drug in

17 Patients with resected stage III colon cancer who were 18 years of age or older, with an Eastern Cooperative On

18 Inclusion criteria required participants to be men who were 18 years of age or older, had had sex with a man in the

19 ccounted for 0.6 percent of all infants born to mothers who were 20 years of age or older in 1997, but for 3.5 percent of

20 irth at less than 20 years of age (n = 1,101) and those who were 20 years of age or older (n = 2,846).

21 ily the result of increased detection of CIN3+ in women who were 30 years of age or older and were cytologically negative

22 We randomly assigned 2079 men and women who were 35 years of age or older and who had had one or more his

23 andomized, controlled trial involving primigravid women who were 35 years of age or older.

24 f age and had undergone subtotal resection or biopsy or who were 40 years of age or older and had undergone biopsy or res

25 rs of age and had undergone subtotal tumor resection or who were 40 years of age or older, progression-free survival and

26 Patients who were 40 years of age or older, as compared with those under t

27 Among patients who were 40 years of age or older, the corresponding rates were 4

28 in starting 14 days or more after vaccination in adults who were 50 years of age or older.

29 gnificantly reduced the risk of herpes zoster in adults who were 50 years of age or older.

30 The authors who were 50 years of age or older, from the United States, had Ph

31 We enrolled 2016 patients who were 50 years of age or older, who had either a history of or

32 The decrease was evident only in women who were 50 years of age or older and was more evident in cancers

33 Persons with hypertension who were 55 years of age or older with 1 or more risk factors for

34 Among patients with a recent cryptogenic stroke or TIA who were 55 years of age or older, paroxysmal atrial fibrillation

35 he Cystic Fibrosis Foundation National Patient Registry who were 6 years of age or older in 1996.

36 Of 181 trial participants (103 female [56.9%]) who were 60 years of age or older and whose major depression had

37 uestionnaire about treatment preferences to 226 persons who were 60 years of age or older and who had a limited life expe

38 rticipants (42% women) in 11 prospective cohort studies who were 60 years of age or older at enrollment (in 1988-2005).

39 Those who were 60 years of age or older at entry were at lower risk of

40 n a nationally representative sample of Canadian adults who were 65 years of age or older (n = 14,881) from the Canadian

41 bined effects of weight loss and exercise in 107 adults who were 65 years of age or older and obese.

42 060 patients with AF who required long-term therapy and who were 65 years of age or older or who had another risk factor

43 Medicare beneficiaries who were 65 years of age or older, were hospitalized with an acut

44 with standard chemotherapy in women with breast cancer who were 65 years of age or older.

45 Vaccine efficacy in adults who were 70 years of age or older was similar to that in the othe

46 The findings were similar when data on patients who were 70 years of age or older were analyzed, when 15 trials t

47 of medical services per 1000 person-years among persons who were 70 years of age or older.

48 1994 and February 1999, we randomly assigned 636 women who were 70 years of age or older and who had clinical stage I (T

49 who were younger than 55 years of age (44.3%) and those who were 85 years of age or older (35.4%).

50 among persons less than two years old than among those who were two years of age or older (relative risk, 1.51; 95 perce